We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Four-Biomarker Panel Could Enable Early Ovarian Cancer Detection

By LabMedica International staff writers
Posted on 16 Jan 2024

Ovarian cancer remains a significant cause of mortality globally. More...

While advancements in cytoreductive surgery and chemotherapy have improved survival for those with epithelial ovarian cancer, prognosis heavily depends on the stage at diagnosis. Early detection, particularly at stage I, offers a five-year survival rate exceeding 90%. However, this rate drops to around 70% for stage II, where cancer is confined to the pelvis, and declines further for later stages, plummeting to a mere 20% at stage IV. Computational models suggest that detecting ovarian cancer in stages I or II could increase the cure rate by 10-30%. Currently, Cancer Antigen 125 (CA125), a protein found in various cells, including those of ovarian cancer, is the only tumor marker recommended for clinical use in diagnosing and managing ovarian cancer. Now, a new study has shown that a panel of four biomarkers is more sensitive than CA125 alone for early ovarian cancer detection, maintaining the same specificity.

In this study, conducted in collaboration with the Early Detection Research Network (EDRN, Bethesda, MD, USA), researchers compared a range of antigens, autoantibodies (AAb), and antigen-autoantibody (Ag-AAb) complexes alongside CA125 for early ovarian cancer detection. The study involved measuring 26 biomarkers in a single sera panel from women with early (I-II) and late (III-IV) stage ovarian cancers, benign pelvic masses, and healthy controls. The participants were randomly divided into a training set to identify the most effective classifier and a validation set to evaluate its performance against CA125 alone. The research identified eight biomarkers capable of detecting ≥8% of early-stage cases at 98% specificity. A panel comprising four biomarkers — CA125, HE4, HE4 Ag-AAb, and osteopontin — identified 75% of early-stage cancers among healthy controls in the validation set, compared to 62% detection using CA125 alone (p = 0.003), maintaining 98% specificity.

This panel also showed a 25% increase in sensitivity over CA125 alone in differentiating early-stage ovarian cancers from benign pelvic masses (p = 0.0004) at 95% specificity. From the 21 autoantibody candidates, three (anti-p53, anti-CTAG1, and anti-Il-8) identified 22% of early-stage ovarian cancers, potentially offering a diagnostic lead time. The study thus pinpointed three biomarkers — HE4, HE4 Ag-AAb complexes, and osteopontin — that effectively complement CA125, potentially increasing early detection of ovarian cancer at 98% specificity. This method could offer a significant lead time of over 18 months in some cases, a crucial factor for the effectiveness of treatment.

Related Links:
EDRN


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.